Próstata

Produção Científica

Underexpression of MMP-2 and its regulators, TIMP2, MT1-MMP and IL-8, is associated with prostate cancer.
Reis ST, Antunes AA, Pontes J Jr, de Sousa-Canavez JM, Dall'Oglio MF, Piantino CB, da Cruz JA, Morais DR, Srougi M, Leite KR.
Int Braz J Urol. 2012 Mar-Apr;38(2):167-74.
 
MMP-9 overexpression due to TIMP-1 and RECK underexpression is associated with prognosis in prostate cancer.
Reis ST, Pontes-Junior J, Antunes AA, de Sousa-Canavez JM, Dall'Oglio MF, Passerotti CC, Abe DK, Crippa A, da Cruz JA, Timoszczuk LM, Srougi M, Leite KR.
Int J Biol Markers. 2011 Oct-Dec;26(4):255-61. doi: 10.5301/JBM.2011.8831.
 
Socioeconomic status is an independent predictor of biochemical recurrence among patients with prostate cancer who undergo radical prostatectomy.
Srougi V, Antunes AA, Reis ST, Dall'oglio MF, Nesrallah AJ, Leite KR, Srougi M.
Int Braz J Urol. 2011 Jul-Aug;37(4):507-13.
 
Tgf-β1 expression as a biomarker of poor prognosis in prostate cancer.
Reis ST, Pontes-Júnior J, Antunes AA, Sousa-Canavez JM, Abe DK, Cruz JA, Dall'oglio MF, Crippa A, Passerotti CC, Ribeiro-Filho LA, Viana NI, Srougi M, Leite KR.
Clinics (Sao Paulo). 2011;66(7):1143-7.
 
Perineural invasion detection in prostate biopsy is related to recurrence-free survival in patients submitted to radical prostatectomy.
Katz B, Srougi M, Dall'oglio M, Nesrallah AJ, Sant'anna AC, Pontes J Jr, Antunes AA, Reis ST, Viana N, Sañudo A, Camara-Lopes LH, Leite KR.
Urol Oncol. 2011 Jul 25. [Epub ahead of print].
 
Urinary incontinence following surgery for BPH: the role of aging on the incidence of bladder dysfunction.
Bruschini H, Simonetti R, Antunes AA, Srougi M.
Int Braz J Urol. 2011 May-Jun;37(3):380-6; discussion 387.
 
Midterm follow-up after prostate embolization in two patients with benign prostatic hyperplasia.
Carnevale FC, da Motta-Leal-Filho JM, Antunes AA, Baroni RH, Freire GC, Cerri LM, Marcelino AS, Cerri GG, Srougi M.
Cardiovasc Intervent Radiol. 2011 Dec;34(6):1330-3.
 
The use of immunohistochemistry for diagnosis of prostate cancer.
Leite KR, Srougi M, Sanudo A, Dall'oglio MF, Nesrallah A, Antunes AA, Cury J, Camara-Lopes LH.
Int Braz J Urol. 2010 Sep-Oct;36(5):583-90.
 
Prostate biopsy in patients with long-term use of indwelling bladder catheter: What is the rationale?
Antunes AA, Barbosa JA, Reis ST, Guariero MS, Fukushima JT, Dall'oglio MF, Freire GD, Lucon AM, Leite KR, Srougi M.
Urol Oncol. 2010 Oct 6. [Epub ahead of print].
 
Tumor banks: the cornerstone of basic research in urology.
Reis ST, Feitosa EB, Pontes-Junior J, Marin CC, Abe DK, Crippa A, Antunes AA, Nesrallah AJ, Oliveira LC, Ribeiro-Filho LA, Srougi M, Leite KR, Dall'Oglio MF.
Int Braz J Urol. 2010 May-Jun;36(3):348-54. Review.
 
Association between integrin expression and prognosis in localized prostate cancer.
Pontes-Júnior J, Reis ST, de Oliveira LC, Sant'anna AC, Dall'oglio MF, Antunes AA, Ribeiro-Filho LA, Carvalho PA, Cury J, Srougi M, Leite KR.
Prostate. 2010 Aug;70(11):1189-95.
 
Long-term outcomes of radical cystectomy with preservation of prostatic capsule.
Dall'Oglio MF, Antunes AA, Crippa A, Nesrallah AJ, Srougi M.
Int Urol Nephrol. 2010 Dec;42(4):951-7. Epub 2010 May 20.
 
Transurethral resection of the prostate for the treatment of lower urinary tract symptoms related to benign prostatic hyperplasia: how much should be resected?
Antunes AA, Srougi M, Coelho RF, Leite KR, Freire Gde C.
Int Braz J Urol. 2009 Nov-Dec;35(6):683-9; discussion 689-91.
 
GREB1 tissue expression is associated with organ-confined prostate cancer.
Antunes AA, Leite KR, Reis ST, Sousa-Canavez JM, Camara-Lopes LH, Dall'oglio MF, Srougi M.
Urol Oncol. 2012 Jan-Feb;30(1):16-20. Epub 2009 Nov 27.
 
Prostatic artery embolization as a primary treatment for benign prostatic hyperplasia: preliminary results in two patients.
Carnevale FC, Antunes AA, da Motta Leal Filho JM, de Oliveira Cerri LM, Baroni RH, Marcelino AS, Freire GC, Moreira AM, Srougi M, Cerri GG.
Cardiovasc Intervent Radiol. 2010 Apr;33(2):355-61. Epub 2009 Nov 12.
 
Change in expression of miR-let7c, miR-100, and miR-218 from high grade localized prostate cancer to metastasis.
Leite KR, Sousa-Canavez JM, Reis ST, Tomiyama AH, Camara-Lopes LH, Sañudo A, Antunes AA, Srougi M.
Urol Oncol. 2011 May-Jun;29(3):265-9. Epub 2009 Apr 16.
 
Genetic polymorphisms of matrix metalloproteinases: susceptibility and prognostic implications for prostate cancer.
Dos Reis ST, Pontes J Jr, Villanova FE, Borra PM, Antunes AA, Dall'oglio MF, Srougi M, Leite KR.
J Urol. 2009 May;181(5):2320-5. Epub 2009 Mar 19. Erratum in: J Urol. 2009 Jul;182(1):400.
 
Matrix metalloproteinase-2 polymorphism is associated with prognosis in prostate cancer.
dos Reis ST, Villanova FE, Andrade PM, Pontes J Jr, de Sousa-Canavez JM, Sañudo A, Antunes AA, Dall'oglio MF, Srougi M, Moreira Leite KR.
Urol Oncol. 2010 Nov-Dec;28(6):624-7. Epub 2008 Dec 30.
 
The role of prostate specific membrane antigen and pepsinogen C tissue expression as an adjunctive method to prostate cancer diagnosis.
Antunes AA, Leite KR, Sousa-Canavez JM, Camara-Lopes LH, Srougi M.
J Urol. 2009 Feb;181(2):594-600. Epub 2008 Dec 13.
 
Patient's reactions to digital rectal examination of the prostate.
Furlan AB, Kato R, Vicentini F, Cury J, Antunes AA, Srougi M.
Int Braz J Urol. 2008 Sep-Oct;34(5):572-5; discussion 576.
 
The role of extended prostate biopsy on prostate cancer detection rate: a study performed on the bench.
Nesrallah L, Nesrallah A, Antunes AA, Leite KR, Srougi M.
Int Braz J Urol. 2008 Sep-Oct;34(5):563-70; discussion 570-1.
 
Gnathic bone metastasis: a retrospective study of 10 cases.
Antunes AA, Antunes AP.
Braz J Otorhinolaryngol. 2008 Jul-Aug;74(4):561-5.
 
Upgrading the Gleason score in extended prostate biopsy: implications for treatment choice.
Moreira Leite KR, Camara-Lopes LH, Dall'Oglio MF, Cury J, Antunes AA, Sañudo A, Srougi M.
Int J Radiat Oncol Biol Phys. 2009 Feb 1;73(2):353-6. Epub 2008 Sep 5.
 
Cdx2, cytokeratin 20, thyroid transcription factor 1, and prostate-specific antigen expression in unusual subtypes of prostate cancer.
Leite KR, Mitteldorf CA, Srougi M, Dall'oglio MF, Antunes AA, Pontes J Jr, Camara-Lopes LH. Ann
Diagn Pathol. 2008 Aug;12(4):260-6. Epub 2008 Apr 18.
 
The effect of the number of biopsy cores on the concordance between prostate biopsy and prostatectomy Gleason score: a prostate volume-controlled study.
Antunes AA, Leite KR, Dall'Oglio MF, Cury J, Srougi M.
Arch Pathol Lab Med. 2008 Jun;132(6):989-92.
 
The York-Mason technique for recto-urethral fistulas.
Crippa A, Dall'oglio MF, Nesrallah LJ, Hasegawa E, Antunes AA, Srougi M.
Clinics (Sao Paulo). 2007 Dec;62(6):699-704.
 
The role of BPH, lower urinary tract symptoms, and PSA levels on erectile function of Brazilian men who undergo prostate cancer screening.
Antunes AA, Srougi M, Dall'oglio MF, Vicentini F, Paranhos M, Freire GC.
J Sex Med. 2008 Jul;5(7):1702-7.
 
Preoperative determination of prostate cancer tumor volume: analysis through biopsy fragments.
Antunes AA, Srougi M, Dall'Oglio MF, Crippa A, Nesrallah AJ, Nesrallah LJ, Leite KR.
Int Braz J Urol. 2007 Jul-Aug;33(4):477-83; discussion 484-5.
 
Botulinum toxin for the treatment of lower urinary tract symptoms due to benign prostatic hyperplasia.
Antunes AA, Srougi M, Coelho RF, de Campos Freire G.
Nat Clin Pract Urol. 2007 Mar;4(3):155-60. Review.
 
Microvascular invasion is an independent prognostic factor in patients with prostate cancer treated with radical prostatectomy.
Antunes AA, Srougi M, Dall'Oglio MF, Crippa A, Paranhos M, Cury J, Nesrallah LJ, Leite KR.
Int Braz J Urol. 2006 Nov-Dec;32(6):668-75; discussion 675-7.
 
Analysis of the risk factors for incidental carcinoma of the prostate in patients with benign prostatic hyperplasia.
Antunes AA, Freire Gde C, Aiello Filho D, Cury J, Srougi M.
Clinics (Sao Paulo). 2006 Dec;61(6):545-50.
 
A new nomogram to predict pathologic outcome following radical prostatectomy.
Crippa A, Srougi M, Dall'Oglio MF, Antunes AA, Leite KR, Nesrallah LJ, Ortiz V.
Int Braz J Urol. 2006 Mar-Apr;32(2):155-64.
 
Age impact in clinicopathologic presentation and the clinical evolution of prostate cancer in patients submitted to radical prostatectomy.
Antunes AA, Crippa A, Dall'Oglio MF, Nesrallah LJ, Leite KR, Srougi M.
Int Braz J Urol. 2006 Jan-Feb;32(1):48-55.
 
The percentage of positive biopsy cores as a predictor of disease recurrence in patients with prostate cancer treated with radical prostatectomy.
Antunes AA, Srougi M, Dall'Oglio MF, Crippa A, Campagnari JC, Leite KR.
BJU Int. 2005 Dec;96(9):1258-63.
 
Prostate biopsy: is age important for determining the pathological features in prostate cancer?
Antunes AA, Leite KR, Dall'Oglio MF, Crippa A, Nesrallah LJ, Srougi M.
Int Braz J Urol. 2005 Jul-Aug;31(4):331-7.
 
Inguinal hernia repair with polypropylene mesh during radical retropubic prostatectomy: an easy and practical approach.
Antunes AA, Dall'oglio M, Crippa A, Srougi M.
BJU Int. 2005 Aug;96(3):330-3.
 
Survival of patients with prostate cancer and normal PSA levels treated by radical prostatectomy.
Dall'oglio MF, Crippa A, Antunes AA, Nesrallah LJ, Leite KR, Srougi M.
Int Braz J Urol. 2005 May-Jun;31(3):222-7.
 
Prognostic value of the percentage of positive fragments in biopsies from patients with localized prostate cancer.
Antunes AA, Dall'Oglio MF, Sant'Anna AC, Paranhos M, Leite KR, Srougi M.
Int Braz J Urol. 2005 Jan-Feb;31(1):34-41.
 
Analysis of risk factors of involvement of seminal vesicles in patients with prostate cancer undergoing radical prostatectomy.
Dall'Oglio MF, Sant'Anna AC, Antunes AA, Nesrallah LJ, Leite KR, Srougi M.
Int Braz J Urol. 2004 Nov-Dec;30(6):472-8.
 
Primary lymphoma of the prostate: a rare cause of urinary obstruction.
Antunes AA, Dall'Oglio M, Srougi M.
Int Braz J Urol. 2004 Sep-Oct;30(5):410-2.
 
Efficacy of intrarectal lidocaine hydrochloride gel for pain control in patients undergoing transrectal prostate biopsy.
Antunes AA, Calado AA, Lima MC, Falcão E.
Int Braz J Urol. 2004 Sep-Oct;30(5):380-3.